MSB 2023 - awaiting for Ryoncil approval, page-619

The effect on trust is two fold. First we should look at tust in SI and MSB. This over the last few months has been restored or at least heading in the right direction. The other side is trust in the FDA, I see this turning, the distrust at the time of the CRL was very much the driver of the SP yet now we can see why the FDA did what they did and in the longer term there actions will result in a far better trial results. So the distrust was way over the top. At the same time the FDA lost trust in the broarder market, this would have had significants to all biotechs.